Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands.
| Autor: | Woestenberg, Petra J, King, Audrey J, Benthem, Birgit H B Van, Leussink, Suzan, Sande, Marianne A B Van der, Hoebe, Christian J P A, Bogaards, Johannes A, Services, Medical Microbiological Laboratories and the Public Health, Van Benthem, Birgit H B, Van der Sande, Marianne A B, Medical Microbiological Laboratories and the Public Health Services |
|---|---|
| Předmět: |
VACCINE effectiveness
SEXUALLY transmitted diseases ANAL cancer PAPILLOMAVIRUSES ANUS COMPARATIVE studies FEMALE reproductive organ diseases IMMUNITY IMMUNIZATION RESEARCH methodology MEDICAL cooperation PAPILLOMAVIRUS diseases RESEARCH COMBINED vaccines HUMAN papillomavirus vaccines EVALUATION research CROSS-sectional method |
| Zdroj: | Journal of Infectious Diseases; 4/15/2020, Vol. 221 Issue 8, p1280-1285, 6p |
| Abstrakt: | Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|